| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -32.1 | -41.9 |
| Net income | -32.2 | -42.0 |
| EPS (diluted, $ a share) | $-0.40 | $-0.53 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: AVIR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Atea Pharmaceuticals, Inc.: key numbers
- Share price
- $4.12Close, Nov 16
- Market cap
- $331M
- Shares outstanding
- 80.3MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Atea Pharmaceuticals, Inc.
All →Atea Pharmaceuticals Financial Results
Atea Pharmaceuticals reported Q3 2026 financial results and provided a clinical update on its Phase 3 C-BEYOND trial for Hepatitis C, which met its primary and secondary endpoints. The company also secured up to $200 million in non-dilutive funding from Hercules Capital and expects topline results from its Phase 3 C-FORWARD trial in early 2027.
- Term
- Q3 2026
“The C-BEYOND results are strong and reinforce our conviction that the regimen of BEM/RZR will deliver a differentiated profile, including high HCV cure rates, short treatment duration, a low risk of drug-drug interactions and no food effect, which we believe are critical to drive broad adoption of BEM/RZR in clinical practice by prescribers.”
Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals
“We anticipate the upcoming topline Phase 3 results of C-FORWARD should further validate the potential of BEM/RZR, if approved, to be a new pan-genotypic treatment option for prescribers to treat people living with HCV.”
Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals
Atea Pharmaceuticals $200M Debt Financing with Hercules Capital, Inc.
Atea Pharmaceuticals entered into a $200 million senior secured term loan facility with Hercules Capital, with an initial $65 million drawn at closing. Additional tranches are available upon achieving clinical and commercial milestones related to the bemnifosbuvir and ruzasvir (BEM/RZR) program. The facility matures in November 2031 and carries a floating interest rate starting at a minimum of 9.35%.
- Value
- $200M
- Counterparty
- Hercules Capital, Inc.
- Term
- through Nov 2031